ATE219681T1 - Behandlung von krebs durch verwendung von hsv- mutanten - Google Patents

Behandlung von krebs durch verwendung von hsv- mutanten

Info

Publication number
ATE219681T1
ATE219681T1 AT95927034T AT95927034T ATE219681T1 AT E219681 T1 ATE219681 T1 AT E219681T1 AT 95927034 T AT95927034 T AT 95927034T AT 95927034 T AT95927034 T AT 95927034T AT E219681 T1 ATE219681 T1 AT E219681T1
Authority
AT
Austria
Prior art keywords
treating cancer
mutant
gamma
gene
hsv mutants
Prior art date
Application number
AT95927034T
Other languages
English (en)
Inventor
Alasdair Roderick Maclean
Susanne Moira Brown
Nigel William Fraser
Bruce Paul Randazzo
Original Assignee
Univ Glasgow
Wistar Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10759079&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE219681(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Glasgow, Wistar Inst filed Critical Univ Glasgow
Application granted granted Critical
Publication of ATE219681T1 publication Critical patent/ATE219681T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AT95927034T 1994-07-29 1995-07-28 Behandlung von krebs durch verwendung von hsv- mutanten ATE219681T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9415320A GB9415320D0 (en) 1994-07-29 1994-07-29 Cancer treatment
PCT/GB1995/001791 WO1996003997A2 (en) 1994-07-29 1995-07-28 Treatment of cancer using hsv mutant

Publications (1)

Publication Number Publication Date
ATE219681T1 true ATE219681T1 (de) 2002-07-15

Family

ID=10759079

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95927034T ATE219681T1 (de) 1994-07-29 1995-07-28 Behandlung von krebs durch verwendung von hsv- mutanten

Country Status (12)

Country Link
US (3) US7674468B2 (de)
EP (2) EP0773785B1 (de)
JP (2) JP4321723B2 (de)
AT (1) ATE219681T1 (de)
AU (1) AU3119995A (de)
CA (1) CA2196315C (de)
DE (1) DE69527204T2 (de)
DK (1) DK0773785T3 (de)
ES (1) ES2179880T3 (de)
GB (1) GB9415320D0 (de)
PT (1) PT773785E (de)
WO (1) WO1996003997A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9415320D0 (en) * 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
ZA966287B (en) * 1995-07-27 1998-03-09 American Cyanamid Co Avirulent herpetic viruses useful as tumoricidal agents and vaccines.
ATE241994T1 (de) * 1996-01-25 2003-06-15 Univ Glasgow Hsv-mutant-1716 zur behandlung von mesotheliomen
US5824318A (en) * 1996-07-24 1998-10-20 American Cyanamid Company Avirulent herpetic viruses useful as tumoricidal agents and vaccines
GB9615794D0 (en) 1996-07-26 1996-09-04 Medical Res Council Mutant herpes simplex virus strains and uses thereof
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
US7780962B2 (en) 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
NZ550861A (en) 1999-04-15 2009-03-31 Wellstat Biologics Corp Treatment of neoplasms with viruses
US6897057B1 (en) 1999-08-31 2005-05-24 The General Hospital Corporation Cell-specific and/or tumor-specific promoter retargeting of herpes γ 34.5 gene expression
CA2383372C (en) * 1999-08-31 2010-04-13 The General Hospital Corporation Cell-specific and/or tumor-specific promoter retargeting of herpes gamma 34.5 gene expression
DE60041210D1 (de) 1999-09-17 2009-02-05 Wellstat Biologics Corp Onkolytisches Virus
US8147822B1 (en) 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
ES2366608T3 (es) 2001-03-27 2011-10-21 The General Hospital Corporation Vectores víricos y su uso en métodos terapéuticos.
GB0203285D0 (en) 2002-02-12 2002-03-27 Brown Susanne M An herpes simplex virus complex
JP2004099584A (ja) 2002-05-02 2004-04-02 Keio Gijuku Ｈｓｖを用いた抗腫瘍剤
NZ541951A (en) 2003-03-07 2008-03-28 Robarts Res Inst Use of myxoma virus for the therapeutic treatment of cancer and chronic viral infection
US7731974B2 (en) 2003-03-27 2010-06-08 Ottawa Hospital Research Institute Mutant vesicular stomatitis viruses and uses thereof
AU2004223808B2 (en) 2003-03-27 2009-03-26 Ottawa Health Research Institute Mutant vesicular stomatitis viruses and use thereof
US7897146B2 (en) 2003-11-17 2011-03-01 Crusade Laboratories Limited Treatment using herpes simplex virus
JP2007511216A (ja) 2003-11-17 2007-05-10 クルセイド ラボラトリーズ リミテッド 変異ウイルス
CA2600675C (en) 2005-03-07 2015-12-15 Robarts Research Institute Use of a combination of myxoma virus and rapamycin for therapeutic treatment
CN102026645B (zh) 2006-09-15 2016-01-27 渥太华医院研究机构 溶瘤弹状病毒
RU2751236C2 (ru) * 2016-04-22 2021-07-12 Иммвира Ко., Лимитед КОНСТРУИРОВАНИЕ ОБЛИГАТНОГО ВЕКТОРА НА ОСНОВЕ ОНКОЛИТИЧЕСКИХ ВИРУСОВ ПРОСТОГО ГЕРПЕСА (oHSV) И КОНСТРУКЦИИ ДЛЯ ТЕРАПИИ РАКА
JP2023540548A (ja) * 2020-09-04 2023-09-25 イノブストーン セラピューティクス リミテッド 抗腫瘍活性を有する化合物及びその使用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859587A (en) 1984-06-04 1989-08-22 Institut Merieux Recombinant herpes simplex viruses, vaccines and methods
US5328688A (en) 1990-09-10 1994-07-12 Arch Development Corporation Recombinant herpes simplex viruses vaccines and methods
CA2051289C (en) * 1990-09-14 2002-11-26 Robert L. Martuza Viral mediated destruction of neoplastic cells
GB9102126D0 (en) * 1991-01-31 1991-03-13 Smithkline Beecham Biolog Novel vaccine
ES2183811T3 (es) 1992-03-31 2003-04-01 Arch Dev Corp Tratamiento de enfermedades tumorigenas con un hsv modificado.
US6139834A (en) 1994-06-23 2000-10-31 Georgetown University Replication-competent Herpes simplex virus mediates destruction of neplastic cells
US5585096A (en) * 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
US5728379A (en) 1994-06-23 1998-03-17 Georgetown University Tumor- or cell-specific herpes simplex virus replication
GB9415320D0 (en) * 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
JPH11513390A (ja) 1995-10-06 1999-11-16 アーチ デベロップメント コーポレイション 細胞殺傷のウイルス増強のための方法および組成物
ATE241994T1 (de) 1996-01-25 2003-06-15 Univ Glasgow Hsv-mutant-1716 zur behandlung von mesotheliomen
GB0203285D0 (en) 2002-02-12 2002-03-27 Brown Susanne M An herpes simplex virus complex
GB0326798D0 (en) 2003-11-17 2003-12-24 Crusade Lab Ltd Methods for generating mutant virus
WO2007026146A1 (en) 2005-08-30 2007-03-08 Crusade Laboratories Limited Treatment using herpes simplex virus
JP2007511216A (ja) 2003-11-17 2007-05-10 クルセイド ラボラトリーズ リミテッド 変異ウイルス
EP2016182B8 (de) 2006-05-11 2015-09-02 Virttu Biologics Limited Mutantes hsv, materialien und verfahren zur erzeugung des mutanten hsv
US8163292B2 (en) 2007-02-16 2012-04-24 Virttu Biologics Limited Herpes simplex viruses and methods of viral replication
GB0714578D0 (en) 2007-07-26 2007-09-05 Crusade Lab Ltd Viruses

Also Published As

Publication number Publication date
WO1996003997A3 (en) 1996-05-02
AU3119995A (en) 1996-03-04
JP4321723B2 (ja) 2009-08-26
US20050260169A1 (en) 2005-11-24
EP0773785B1 (de) 2002-06-26
WO1996003997A2 (en) 1996-02-15
EP1192948A2 (de) 2002-04-03
US7674468B2 (en) 2010-03-09
DE69527204T2 (de) 2003-02-20
US8067012B2 (en) 2011-11-29
DK0773785T3 (da) 2002-10-07
US20120141418A1 (en) 2012-06-07
EP1192948A3 (de) 2002-09-04
CA2196315C (en) 2010-02-09
GB9415320D0 (en) 1994-09-21
JP2008037869A (ja) 2008-02-21
JPH10503766A (ja) 1998-04-07
ES2179880T3 (es) 2003-02-01
EP0773785A2 (de) 1997-05-21
PT773785E (pt) 2002-11-29
US20100172872A1 (en) 2010-07-08
CA2196315A1 (en) 1996-02-15
DE69527204D1 (de) 2002-08-01

Similar Documents

Publication Publication Date Title
DE69527204D1 (de) Behandlung von krebs durch verwendung von hsv-mutanten
TR199701545T1 (xx) Yeni dolastatin t�revleri,haz�rlanmalar� ve kullan�mlar�
FI853622A0 (fi) Diarylacetylener, deras framstaellning och anvaendning.
EP0290133A3 (de) Ternar-Photoinitiatorsystem für Additionspolymerisation
DK0555370T3 (da) Metoder og anvendelser for effektive, genetiske suppressorelementer
GEP20002331B (en) Alkylated Raphamicine Derivatives
SE9103183L (sv) Virus-antikroppskomplex
AU1550797A (en) Treatment of non-neuronal cancer using hsv mutant
DE69731756D1 (de) Melanomzellinien, welche immundominante melanomantigene teilen und verfahren zu deren anwendung
BR8402533A (pt) Polimero,processo para sua preparacao,e sua aplicacao
DK0642530T3 (da) Dolastatinderivater
EP0389428A3 (de) N,N-Bis(1-hydroxycarbyloxy-2,2,6,6-tetramethyl-piperidin-4-yl) aminotriazine und damit stabilisierte Mischungen
GR3031149T3 (en) Process for the manufacture of (s)-3-amino-1-substituted-pyrrolidines.
ATE187722T1 (de) Cycloaliphatische acryloyl-monomere
FI98987B (fi) Varjoainekoostumus
DE3888887D1 (de) Monoklonale Antikörper gegen E7-Protein des Humanen Papillomvirus Typ 16, Verfahren zu ihrer Herstellung sowie ihre Verwendung.
FI913468A0 (fi) Hiomakivi
DE3689853D1 (de) Verwendung von Gyrasehemmern zur Dekontamination von Mycoplasma-infizierten Zellkulturen.
FI882444A0 (fi) Substituerade vinylkefalosporiner, foerfarande foer deras framstaellning och deras anvaendning som laekemedel.
DE59000772D1 (de) Seitenstaendige carbazolyl-gruppen enthaltende methacrylat-(co)polymerisate und elektrophotographische aufzeichnungselemente, enthaltend dieselben.
ATE84780T1 (de) Neue di(meth)acrylate, verfahren zu deren herstellung und deren verwendung.
ATE117772T1 (de) Montageelement.
ATE34987T1 (de) Neue antibiotika, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel und zwischenprodukte zu ihrer herstellung.
ZA818683B (en) Trifluoromethoxyphenyl-(di)thiophosphoric acid esters and their use in pest control
Yi Negative effect of nepotism on the development of Korean society and an exploration of an alternative

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification